Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA
wet age-related macular degeneration
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for ONS-5010/LYTENAVA in wet age-related macular degeneration are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“NORSE EIGHT did not meet its primary endpoint at 8 weeks, the study demonstrated a positive trajectory consistent with NORSE TWO through 12 weeks of treatment and provided important functional and mechanistic/pharmacodynamic evidence of eff”